[go: up one dir, main page]

UY25441A1 - Procedimiento para la preparacion de formas galenicas de meloxicam para la aplicacion oral. - Google Patents

Procedimiento para la preparacion de formas galenicas de meloxicam para la aplicacion oral.

Info

Publication number
UY25441A1
UY25441A1 UY25441A UY25441A UY25441A1 UY 25441 A1 UY25441 A1 UY 25441A1 UY 25441 A UY25441 A UY 25441A UY 25441 A UY25441 A UY 25441A UY 25441 A1 UY25441 A1 UY 25441A1
Authority
UY
Uruguay
Prior art keywords
salt
meloxicam
procedure
preparation
oral application
Prior art date
Application number
UY25441A
Other languages
English (en)
Inventor
Thomas Bock Dr
Sägmüller Paul
Peter Sieger Dr
Dietrich Türck Dr
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of UY25441A1 publication Critical patent/UY25441A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procedimiento para la preparación de una forma medicamentosa sólida de Meloxicam, que pertenece a los fármacos no esteroides anti-inflamatorios, aplicable por vía oral, que posee un corto tiempo de descomposición y de la que se libera y absorbe rápidamente el principio activo, para la terapia de dolores. Este procedimiento está caracterizado porque una sal de Meloxicam, eventualmente pulverizada, de una base inorgánica u orgánica, preferiblemente la sal de sodio, potasio o amonio, la sal de Meglumina, la sal Tris o la sal de un aminoácido de carácter básico, se mezcla íntimamente con coadyuvantes y/o sustancias de soporte pulverizados adecuados y, sin granulación del polvo antes del prensado, se prensa directamente en tabletas.
UY25441A 1998-03-27 1999-03-24 Procedimiento para la preparacion de formas galenicas de meloxicam para la aplicacion oral. UY25441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98105569A EP0945134A1 (de) 1998-03-27 1998-03-27 Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation

Publications (1)

Publication Number Publication Date
UY25441A1 true UY25441A1 (es) 1999-11-17

Family

ID=8231652

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25441A UY25441A1 (es) 1998-03-27 1999-03-24 Procedimiento para la preparacion de formas galenicas de meloxicam para la aplicacion oral.

Country Status (25)

Country Link
US (1) US6869948B1 (es)
EP (2) EP0945134A1 (es)
JP (1) JP3639532B2 (es)
KR (1) KR100589299B1 (es)
CN (1) CN1163231C (es)
AR (1) AR016197A1 (es)
AT (1) ATE254920T1 (es)
AU (1) AU762322C (es)
BR (1) BR9909192A (es)
CA (1) CA2326517C (es)
DE (1) DE59907871D1 (es)
DK (1) DK1083902T3 (es)
ES (1) ES2212547T3 (es)
HK (1) HK1034183A1 (es)
HU (1) HUP0101246A3 (es)
IL (2) IL137652A0 (es)
NO (1) NO326852B1 (es)
NZ (1) NZ507382A (es)
PL (1) PL192967B1 (es)
PT (1) PT1083902E (es)
TR (1) TR200002786T2 (es)
TW (1) TWI236914B (es)
UY (1) UY25441A1 (es)
WO (1) WO1999049867A1 (es)
ZA (1) ZA200004178B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135127B1 (en) 1998-12-01 2006-01-25 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
AU1548001A (en) * 1999-11-24 2001-06-04 Wakamoto Pharmaceutical Co., Ltd. Ophthalmic aqueous preparation
JP2004506609A (ja) 2000-05-26 2004-03-04 ノボ ノルディスク アクティーゼルスカブ 新たなる医薬組成物及びその調製の為の方法
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
DE10030345A1 (de) * 2000-06-20 2002-01-10 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen
US7120656B1 (en) 2000-10-04 2006-10-10 Marvell International Ltd. Movable tap finite impulse response filter
PL363771A1 (en) * 2001-02-27 2004-11-29 Ranbaxy Laboratories Limited Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
EP1348436A1 (en) * 2002-03-30 2003-10-01 Boehringer Ingelheim International GmbH Meloxicam suppositories
GB0209257D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10250081A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Vetmedica Gmbh Wasserlösliche Meloxicam Granulate
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
EP3662904A1 (de) 2002-11-22 2020-06-10 Grünenthal GmbH (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol zur behandlung von entzündungsschmerz
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
WO2004082593A2 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Pharmaceutical compositions of cetp inhibitors
KR100620239B1 (ko) * 2004-01-05 2006-09-13 신일제약주식회사 용해도 및 안정성이 향상된 경구투여용 멜록시캄 고형제조성물
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh Neue Verwendung von Meloxicam in der Veterinärmedizin
US20060025408A1 (en) * 2004-08-02 2006-02-02 Sundaram Venkataraman Process for the preparation of crystalline form-1 of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
ES2901955T3 (es) 2004-10-08 2022-03-24 Abbvie Inc Sal meglumínica y formas cristalinas de la misma de un farmaco (delafloxacina)
HU227359B1 (en) * 2004-12-18 2011-04-28 Egis Gyogyszergyar Nyilvanosan Mikodi Ruszvunytarsasag Process for producing meloxicam and meloxicam potassium salt of high purity
CA2586288A1 (en) 2004-12-06 2006-06-15 Janssen Pharmaceutica Nv Oral suspension comprising meloxicam
CA2597956C (en) 2005-02-17 2013-07-09 Velcera Pharmaceuticals Transmucosal administration of drug compositions for treating and preventing disorders in animals
EP1793801A1 (en) * 2005-07-15 2007-06-13 Teva Pharmaceutical Industries Ltd. Novel granulation process and granulate produced therefrom
CN101277701A (zh) * 2005-09-30 2008-10-01 贝林格尔·英格海姆维特梅迪卡有限公司 含有美洛昔康的药物制剂
US7572641B2 (en) 2005-11-22 2009-08-11 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising meloxicam and methods of their preparation
EP1965774A2 (en) * 2005-12-30 2008-09-10 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
KR100791160B1 (ko) * 2006-05-30 2008-01-02 조선대학교산학협력단 멜록시캄의 에탄올아민염 및 이를 함유하는 약제학적조성물
US20070281927A1 (en) * 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
US8124603B2 (en) * 2008-01-22 2012-02-28 Thar Pharmaceuticals In vivo studies of crystalline forms of meloxicam
TR200809200A1 (tr) 2008-12-01 2009-12-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Meloksikam içeren farmasötik formülasyonlar
IN2012DN03157A (es) 2009-10-12 2015-09-18 Boehringer Ingelheim Vetmed
AU2010347598B2 (en) 2010-03-03 2014-11-27 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
US8791105B2 (en) 2010-07-14 2014-07-29 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
US20170281640A1 (en) * 2016-04-04 2017-10-05 Productos Maver, S.A. De C.V. Pharmaceutical Compositions Containing a Muscle Relaxant and a Nonsteroidal Anti-Inflammatory Drugs (NSAID)
EP3877385A1 (en) * 2018-11-05 2021-09-15 Mylan Laboratories Ltd. Meloxicam co-crystals
US20220184095A1 (en) 2019-04-22 2022-06-16 Mylan Specialty L.P. Meloxicam co-crystal compositions
CA3200729A1 (en) 2020-11-06 2022-05-12 Mylan Laboratories Ltd Pharmaceutical composition comprising meloxicam
CN112587497A (zh) * 2020-12-25 2021-04-02 苏州中化药品工业有限公司 一种美洛昔康混悬液胶囊剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2756113A1 (de) * 1977-12-16 1979-06-21 Thomae Gmbh Dr K Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
IT1207994B (it) * 1986-01-03 1989-06-01 Therapicon Srl Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
WO1997017978A1 (en) * 1995-11-13 1997-05-22 Pitmy International N.V. Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
EP1007049A1 (en) * 1997-08-27 2000-06-14 Hexal AG New pharmaceutical compositions of meloxicam with improved solubility and bioavailability

Also Published As

Publication number Publication date
DK1083902T3 (da) 2004-03-29
IL137652A0 (en) 2001-10-31
NO20004823D0 (no) 2000-09-26
EP0945134A1 (de) 1999-09-29
TWI236914B (en) 2005-08-01
CA2326517A1 (en) 1999-10-07
KR100589299B1 (ko) 2006-06-14
HUP0101246A3 (en) 2002-08-28
CN1163231C (zh) 2004-08-25
AU762322C (en) 2004-02-12
PL342988A1 (en) 2001-07-16
HK1034183A1 (en) 2001-10-19
HUP0101246A2 (hu) 2002-05-29
CA2326517C (en) 2008-06-10
ES2212547T3 (es) 2004-07-16
JP2002509886A (ja) 2002-04-02
US6869948B1 (en) 2005-03-22
JP3639532B2 (ja) 2005-04-20
PT1083902E (pt) 2004-04-30
EP1083902B1 (de) 2003-11-26
PL192967B1 (pl) 2006-12-29
CN1295478A (zh) 2001-05-16
DE59907871D1 (de) 2004-01-08
ZA200004178B (en) 2002-04-24
BR9909192A (pt) 2000-12-05
NZ507382A (en) 2003-08-29
AR016197A1 (es) 2001-06-20
IL137652A (en) 2006-10-05
NO326852B1 (no) 2009-03-02
NO20004823L (no) 2000-11-22
ATE254920T1 (de) 2003-12-15
AU762322B2 (en) 2003-06-26
EP1083902A1 (de) 2001-03-21
WO1999049867A1 (de) 1999-10-07
TR200002786T2 (tr) 2001-01-22
KR20010034698A (ko) 2001-04-25
AU3417199A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
UY25441A1 (es) Procedimiento para la preparacion de formas galenicas de meloxicam para la aplicacion oral.
ES2194732T3 (es) Composiciones farmaceuticas orales de liberacion controlada de mesalazina.
PE20081114A1 (es) Composiciones farmaceuticas bioadhesivas de agente dual para uso topico
AR042937A2 (es) Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
GT199900203A (es) Composiciones de celecoxib.
AR059723A2 (es) Composicion de altas dosis de ibandronato
AR018109A1 (es) FORMULACIoN GALÉNICA ADMINISTRABLE POR VíA ORAL QUE PERMITE UNA ABSORCIoN MEJORADA DE PRINCIPIOS ACTIVOS, USO DE UN AGENTE MAJORADOR DE ABSORCIoN PARA PREPARAR UNA FORMA DE DOSIFICACIoN ADMINISTRABLE POR VíA ORAL Y PROCEDIMIENTO PARA PREPARAR DICHA FORMULACIoN GALÉNICA
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
AR011069A1 (es) Compuestos amidino, proceso para su preparacion, compuestos intermediarios, formulaciones farmaceuticas que los comprenden, y su uso en la fabricacion de un medicamento como inhibidor de la oxido nitrico sintasa inducible.
ECSP003847A (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
DOP2002000389A (es) Metodo para fabricar una composición farmaceutica de dosis baja que tiene una distribución y potencia del fármaco uniforme
US20110033545A1 (en) Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
HK1096034A1 (en) A solid dosage form comprising a fibrate
CO5160329A1 (es) Metodo para proveer absorcion incrementada de una amina far- maceuticamente aceptable en la sangre de un humano y composi cion que comprende una amina farmaceuticamente un farmaco antiinflamatorio no esteroidal
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
IT1270239B (it) Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
ES2195573T3 (es) Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion.
UY27727A1 (es) Nueva composicion farmacéutica-
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110817